查看文章

The administration of biological agents is potentially affected by IgE‐mediated infusion reactions.

The aim of the study was to evaluate the utility of skin testing in patients who have experienced infliximab (IFX)‐related reactions.

Thirty patients with previous immediate hypersensitivity reaction to IFX, 20 disease‐matched non exposed subjects, 15 IFX‐treated disease‐matched tolerant patients and 15 IFX non‐responder patients were enrolled. Non‐isotype‐specific and IgE anti‐drug antibodies (ADAs) were measured by a double‐capture ELISA kit and ImmunoCAP assay, respectively. Prick and intra‐dermal tests were carried out with the commercial IFX preparation serially diluted.

Skin testing, performed in 23 of 30 reactive patients, resulted positive in 7 of them (30.4%), whereas no positivity was found in other groups of patients. The majority of reactive patients displayed …